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Abstract
Purpose Positron emission tomography (PET) with choline
tracers has found widespread use for the diagnosis of prostate
cancer (PC). However, choline metabolism is not increased in
a considerable number of cases, whereas prostate-specific
membrane antigen (PSMA) is overexpressed in most PCs.
Therefore, a 68Ga-labelled PSMA ligand could be superior
to choline tracers by obtaining a high contrast. The aim of this
study was to compare such a novel tracer with standard
choline-based PET/CT.
Methods Thirty-seven patients with biochemical relapse of
PC [mean prostate-specific antigen (PSA) 11.1±24.1 ng/ml,
range 0.01–116] were retrospectively analysed after 18F-
fluoromethylcholine and 68Ga-PSMA PET/CT within a time
window of 30 days. Radiotracer uptake that was visually con-
sidered as PC was semi-quantitatively analysed by measuring
the maximum standardized uptake values (SUVmax) of
the scans acquired 1 h after injection of 68Ga-PSMA complex
solution (median 132 MBq, range 59–263 MBq) and 18F-
fluoromethylcholine (median 237 MBq, range 114–374 MBq),
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respectively. In addition, tumour to background ratios were
calculated.
Results A total of 78 lesions characteristic for PC were detect-
ed in 32 patients using 68Ga-PSMA PET/CT and 56 lesions
were detected in 26 patients using choline PET/CT. The higher
detection rate in 68Ga-PSMA PET/CT was statistically signif-
icant (p =0.04). In five patients no lesion was found with both
methods. All lesions detected by 18F-fluoromethylcholine PET/
CT were also seen by 68Ga-PSMA PET/CT. In 68Ga-PSMA
PET/CT SUVmax was clearly (>10 %) higher in 62 of 78
lesions (79.1 %) and the tumour to background ratio was
clearly (>10 %) higher in 74 of 78 lesions (94.9 %) when
compared to 18F-fluoromethylcholine PET/CT.
Conclusion 68Ga-PSMA PET/CT can detect lesions charac-
teristic for PC with improved contrast when compared to
standard 18F-fluoromethylcholine PET/CT, especially at low
PSA levels.
Keywords Prostate cancer . PET/CT . Positron emission
tomography . PSMA . Choline
Introduction
Prostate cancer (PC) is the second most frequent cancer and
the sixth leading cause of cancer death in men worldwide [1].
One of the key issues of this tumour entity is to detect
recurrent disease. To date this is a major challenge for all
conventional imaging modalities [2]. Although choline-
based positron emission tomography (PET)/CT is widely used
for this purpose, there have been numerous studies reporting a
low sensitivity and specificity, especially at low prostate-
specific antigen (PSA) levels [3–13]. Consequently, improved
imaging of PC is necessary. One novel promising method is
PET imaging with 18F-FACBC, a new synthetic amino acid.
Recent evaluations by Nanni et al. indicate that this tracer
might be superior when compared to choline PET/CT [14].
In addition, prostate-specific membrane antigen (PSMA)
recently has received increased attention [15–19]. This cell
surface protein is significantly overexpressed in PC cells when
compared to other PSMA-expressing tissues such as kidney,
proximal small intestine or salivary glands [20, 21]. It there-
fore provides a promising target for PC-specific imaging and
therapy [22].
Recently methods have been developed to label PSMA
ligands with 68Ga, 99mTc and radioiodine enabling their use for
PETor single photon emission computed tomography (SPECT)
imaging and therapy [15, 16, 22–24]. Our initial experience with
PET/CT using Glu-NH-CO-NH-Lys-(Ahx)-[68Ga(HBED-CC)]
(68Ga-PSMA) as a 68Ga-labelled PSMA ligand suggests that this
novel tracer can detect PC relapses and metastases with high
contrast by binding to the extracellular domain of PSMA,
followed by internalization [25, 26]. The aim of our study was
to compare this novel tracer with standard choline-based PET/
CT in the diagnostics of patients presenting a biochemical
recurrence of the disease.
Materials and methods
Patient characteristics
For this study we originally selected 38 male patients who
underwent both choline-based PET/CTand 68Ga-PSMA PET/
CTwithin a time window of 30 days. One of the patients was
deleted from the study as the histological evaluation revealed
multiple metastatic and converging lymph node packages.
This precludes radiological differentiation of individual lymph
nodes and a meaningful quantitative comparison of lymph
node detection rate between choline and PSMA PET/CT.
Therefore, the total number of patients analysed in this study
was 37. In all cases there was suspected progressive disease
following prior conventional treatment of PC (e.g. hormone
therapy, chemotherapy, radiation therapy and/or surgery).
All patients signed a written informed consent form for the
purpose of anonymized evaluation and publication of their
data. The quantity of patients presented in this study reflects
our data collected during the past 3 years. Follow-up could be
conducted in 33 of 37 patients up until the time this manu-
script was submitted.
With the exception of patients 26 and 29 (organiza-
tional reasons), all patients were first investigated by
18F-fluoromethylcholine PET/CT. This is currently the
method of choice in routine clinical practice. However, due
to unsatisfying imaging results of choline PET/CT and to
evaluate possible treatment with 131I-labelled PSMA ligands
(therapy data not yet published), further investigation using
68Ga-PSMA PET/CT was suggested. This additional PET
scan was conducted only in case both patients and their
referring physicians gave their consent.
All reported investigations were conducted in accordance
with the Helsinki Declaration and with our national regula-
tions. This study was approved by the Ethics Committee of the
University of Heidelberg (permit S-321/2012).
Patient characteristics are summarized in Table 1.
Twenty-eight patients had previously undergone prostatecto-
my (Table 1, patients 1, 3–4, 7–8, 10–16, 19, 22–23 and 25–
37), whereas nine were treated with prior radiation therapy and
androgen deprivation without surgical removal of the prostate.
The average age was 69.3±7.1 years (range 57–85, median
70.0) with a mean Gleason score (GSC) of 7.4±1.1 (range 5–9,
median 7.0) and a mean PSA level of 11.1±24.1 ng/ml (range
0.01–116, median 4.0 ng/ml). PSA was measured in blood
samples taken at the time of the first PET/CTscan. The average
time between both investigations was 12.1±8.4 days (range 1–
30, median 11.0).
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Fifteen patients (3, 5–14, 16–17 and 19–20) of the present
study have coincidentally been analysed in a different study
evaluating the biodistribution of the PSMA tracer in humans
[26]. This concordance was not intentional. The authors are
convinced that these patients had to be integrated into the
present manuscript instead of being excluded from the novel
study. Their inclusion improves data quality and confirms the
findings of this study.
Imaging
68Ga-PSMA PET/CT was obtained with the 68Ga-labelled
HBED-CC conjugate of the PSMA-specific pharmacophore
Glu-NH-CO-NH-Lys that was synthesized as described pre-
viously [16]. 68Ga3+ was obtained from a 68Ge/68Ga radionu-
clide generator and complexed with the HBED-CC conjugate
as previously published [16, 17]. The final product was
Table 1 Patient characteristics
Grey fields: patients without pathological tracer uptake in both PSMA-ligand and Choline based PET/CT
Framed numbers: patients without pathological findings in Choline-PET/CT only
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formulated in isotonic phosphate-buffered saline (PBS) with
subsequent sterile filtration. The radiolabelling and purifica-
tion of the PSMA ligand was done using an automated mod-
ule. As a consequence, the radiochemical yield was not deter-
mined regularly. Typically, the labelling efficiency (radio-
chemical yield) is >98 % as determined by module validation.
The 68Ga-PSMA complex solution was applied to patients via
an intravenous bolus (mean 139.6±46.3 MBq, range 59–
263 MBq, median 132 MBq). Targeted 68Ga-PSMA was
2 MBq/kg. Variation of injected radiotracer activity was
caused by the short half-life of 68Ga and variable elution
efficiencies obtained during the lifetime of the 68Ge/68Ga
radionuclide generator. However, in our experience with
PSMA PET/CT during the last 3 years, all injected activities
were sufficient in detecting PC (see also in the “Discussion”).
All injections contained 2 nmol PSMA ligand resulting in a
median specific radioactivity of 66 GBq/μmol.
Choline-based PET/CT was performed with 18F-labelled
fluoromethylcholine (IASOcholine®, Iason, Graz, Austria).
The production was according to common radiopharmaceuti-
cal standards and regulations. The choline solution was ap-
plied to patients via an intravenous bolus (mean 241.6±
59.4 MBq, range 114–374 MBq, median 237 MBq). Targeted
choline activity was 3 MBq/kg.
A non-contrast-enhanced CT scan was performed 1 h post
tracer injection using the following parameters: slice thickness
of 5 mm, increment of 0.8 mm, soft tissue reconstruction
kernel, 130 keVand 80 mAs. Immediately after CT scanning,
a whole-body PETwas acquired in 3D (matrix 164×164). For
each bed position (16.2 cm, overlapping scale 4.2 cm) we used
4-min acquisition time with a 15.5-cm field of view (FOV).
The emission data were corrected for randoms, scatter and
decay. Reconstruction was conducted with an ordered subset
expectation maximization (OSEM) algorithm with 2
iterations/8 subsets and Gauss-filtered to a transaxial resolu-
tion of 5 mm at full-width at half-maximum (FWHM). Atten-
uation correction was performed using the low-dose non-
enhanced CT data. PET and CT were performed using the
same protocol for every patient on a Biograph 6 PET/CT
scanner (Siemens, Erlangen, Germany).
Image analysis
Image analysis was performed using an appropriate worksta-
tion and software (Syngo TrueD, Siemens, Erlangen, Germa-
ny). Two board-certified specialists in nuclear medicine with 8
and 9 years of clinical experiences read all data sets indepen-
dently and resolved any disagreements by consensus. Choline
and PSMA PET/CT were analysed in a randomized fashion.
Lesions that were visually considered as suggestive of PC
were counted and analysed with respect to their localization
(local relapses, lymph node, bone and soft tissue metastases)
and to their maximum standardized uptake values (SUVmax)
as it is common practice in daily routine. SUVmax was chosen
due to its higher reproducibility between different investiga-
tors when compared to SUVmean. The latter one is always
dependent on the volume of interest (VOI) drawn by the
investigator, whereas SUVmax is independent [26].
For calculation of the SUV, circular regions of interest were
drawn around areas with focally increased uptake in transaxial
slices and automatically adapted to a three-dimensional vol-
ume of interest at a 70 % isocontour. In the case of suspicious
focal tracer uptake in one investigation and simultaneous
virtually inconspicuous finding in the same area using the
corresponding different PET/CT technique, SUV was mea-
sured in the inconspicuous areas as well.
SUVmax of the same lesions in both PSMA ligand- and
fluoromethylcholine-based PET/CTwere defined as clearly less,
equal or clearly more with intensity differences of ≤10 %, be-
tween −10 and +10% or >10%, respectively. SUV values of the
same lesions in both PSMA ligand- and fluoromethylcholine-
based PET/CT as well as their ratio to background signal (in
SUVmax) were statistically analysed using a Wilcoxon signed
rank test.
When analysing the contrast of lesions with pathological
tracer uptake and therefore visually highly suggestive of PC
(characteristic for PC), several background tissues corre-
sponding to the localization of the lesions were selected. This
method is more accurate and better reflects the contrasting
ability of the imaging modality in the region of interest when
compared to the selection of one general background tissue
that might show differing background uptake than the region
of interest. However, particularly in cases of a variety of
metastases the selection of multiple backgrounds is not always
feasible. For our study we chose the background according to
the following algorithm:
In cases of bone metastases in the vertebral column, of
local relapses, of lung metastases and of liver metastases, we
selected adjacent normal tissue as background. In cases of
non-vertebral bone metastases, we selected the contralateral
normal bone tissue. In cases of soft tissue metastases and of
lymph node metastases, the gluteal musculature was selected
as background.
The selection of two different backgrounds in cases of bone
metastases (vertebral and non-vertebral) as mentioned above
is due to the well-known fact that the background signal in
choline-based PET imaging is higher in the vertebral column
when compared to other skeletal structures (e.g. Fig. 4d). The
statistical differences between the background signal of the
vertebral column and other parts of the skeletal system in
choline PET/CT are described in the “Results”.
Statistical analysis
For statistical analysis, Excel 2010 (Microsoft, Redmond,
WA, USA) and SigmaPlot version 11 software (Systat
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Software, Inc., Chicago, IL, USA) were used. Significance of
differences was evaluated by:
1. Two-sided Wilcoxon signed rank tests for tumour uptake
and contrast in both PET/CT methods.
2. Two-sided paired t tests to evaluate differences concerning
the background signal between choline- and PSMA-based
PET/CT.
3. Two-sided unpaired two-sample t tests to evaluate differ-
ences concerning GSC and applied radioactivity between
groups with and without pathological uptakes.
4. Two-sided Mann–Whitney tests to evaluate differences
concerning PSAvalues between groups with and without
pathological uptakes.
5. Two-sided McNemar test to analyse whether 68Ga-PSMA
PET/CT detects significantly more lesions characteristic
for PC when compared to choline-based PET/CT.
In all cases a p value of <0.05 was considered statistically
significant. Furthermore, regression analysis between PSA
and SUVmax was done for both investigations.
Results
There were no adverse or clinically detectable pharmacolog-
ical effects in any of the patients after injection of both tracers.
In 32 of 37 (86.5 %) patients at least 1 lesion characteristic for
PC was detected in 68Ga-PSMAPET/CT. By contrast, only 26
of 37 (70.3 %) patients presented with pathological findings in
18F-fluoromethylcholine PET/CT.
Using 68Ga-PSMA PET/CT 78 lesions characteristic for PC
were detected in 32 patients and using 18F-fluoromethylcholine
PET/CT 56 lesions were detected in 26 patients. The higher
detection rate in 68Ga-PSMA PET/CT was significant
(McNemar test, p =0.04). In five patients no lesion was found
with both methods (Table 1).
With PSAvalues of 2.82 ng/ml and less, at least one lesion
characteristic for PC was identified in 68.8 % of patients,
while all patients presented with pathological lesions at PSA
values greater than 2.82 ng/ml. Using the same threshold for
18F-fluoromethylcholine PET/CT, 43.8 % of patients
presented with at least one lesion at PSA levels of 2.82 ng/
ml and less. In addition, 90.5 % of the patients presented with
lesions at levels greater than 2.82 ng/ml. All lesions detected
by 18F-fluoromethylcholine PET/CT were also seen in 68Ga-
PSMA PET/CT.
Amongst all 78 lesions characteristic for PC, 40 were
defined as lymph node metastases, 23 as bone metastases,
10 as local relapses and 5 as soft tissue metastases (1 of the
pelvic wall, 1 hepatic, 1 retrovesical and 2 pulmonary PC
metastases, all 5 confirmed by histology).
Figure 1a demonstrates the SUVmax values of all 78 lesions
and their origin. In 68Ga-PSMA PET/CT SUVmax was clearly
(>10 %) higher in 62 of 78 lesions (=79.1 %, which was
significant, p <0.001), clearly (>10 %) lower in 12 lesions
(15.4 %) and was equal to 18F-fluoromethylcholine PET/CT
in 4 lesions (5.5 %).
Figure 1b demonstrates the tumour to background ratio which
was clearly (>10 %) higher in 74 of 78 lesions (=94.9 %, which
was significant, p<0.001) when using 68Ga-PSMA. The four
remaining lesions in two different patients presented with higher
ratios in 18F-fluoromethylcholine PET/CT (Table 1, patients 7
and 27, Fig. 1, lesions 7 and 50–52).
Concerning both SUVmax of lesions and their signal to
background ratio, the most significant differences between
the two imaging methods were observed in lymph node
metastases followed by bone metastases, local relapses
and soft tissue metastases as demonstrated by Fig. 1 and
Tables 2–3 in supplementary data.
Figures 2, 3 and 4 demonstrate selected examples of the
improved contrast when using the PSMA ligand.
In all selected background tissues, tracer uptake (as mea-
sured with SUVmax) was significantly lower in
68Ga-PSMA
PET/CT than in 18F-fluoromethylcholine PET/CT (two-sided
paired t tests): p <0.001 in gluteal musculature, p <0.001 in
vertebral bones, p <0.001 in non-vertebral bones, p =0.014 in
lungs and p <0.001 in the liver.
Specific characteristics of patients with and without patho-
logical findings in 18F-fluoromethylcholine PET/CT are de-
tailed in Table 4 (supplementary data). Between these two
groups, the mean PSA level was significantly lower (two-sided
Mann–Whitney test, p =0.009) and GSC significantly higher in
the group without pathological findings (t test, p =0.038). The
injected dosage was not significantly higher in the group with
pathological findings (t test p =0.87).
Specific characteristics of patients with and without patho-
logical findings in 68Ga-PSMA PET/CT are also detailed in
Table 4 (supplementary data). Between these two groups,
injected dosage (t test, p =0.76) and PSA level (two-sided
Mann–Whitney test, p =0.096) were not significantly lower in
the group without pathological findings. The GSC was not
significantly higher in the group without pathological findings
(t test, p =0.42). There was no relation in the regression
analysis between PSA and SUV values in both choline- and
PSMA-based PET/CT (raw data not shown).
Seven patients with pathological radiotracer uptake in
68Ga-PSMA PET/CT were further investigated by biopsy or
surgery (Table 1, patients 11–13, 16–17, 27 and 32). In all
cases PC was confirmed. No false-positive or false-negative
lesions were found in all of these cases.
In addition, ten patients were treated by selected radiation
therapy (patients 1, 3, 4, 6, 10, 21, 29–31 and 34). In all cases,
PSA decreased significantly after radiation. One patient (35)
was treated by radiation as well, but the first PSA evaluation
after treatment was still pending at the time of manuscript
submission.
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Three patients (18, 25 and 33) were treated with 131I-
labelled PSMA ligands. After treatment, PSA decreased sig-
nificantly as well. Like selective radiation, these therapies
demonstrated also that the PSMA-positive lesions were me-
tastases of PC. Eight patients (7, 8, 20, 23, 24, 26, 28 and 36)
were treated with androgen deprivation therapy (ADT) only.
In all cases, PSA decreased as well. Four patients were re-
ferred for active surveillance (2, 5, 9 and 19) and four other
patients were not available for follow-up (14, 15, 22 and 37).
Further explanation of patients 4 and 36: after initial PET/
CT without pathological findings (part of this study), both
patients were referred for a second PSMA PET/CT 1 year
after the first investigation. In the case of patient 4, one
nodular PSMA-positive lesion in the pelvis was found. This
lesion was retrospectively already existent in the first PET/CT
although it was smaller and did not present with pathological
tracer uptake. In the case of patient 36, multiple lymph node
metastases were found in the second scan only. Therefore, the
first scan was obviously false-negative in both cases.
In summary, PSMA-positive lesions were proven to be PC
by histology in seven cases. In 13 patients, selective radiation
therapy and therapy with 131I-labelled PSMA ligands followed
Fig. 1 SUVmax (a) of all 78 lesions characteristic for PC and their ratio to
background SUVmax (= contrast, b) 1 h post-injection in both
68Ga-
PSMA PET/CT (left columns ) and 18F-fluoromethylcholine PET/CT
(right columns). Green columns indicate lymph node metastases, blue
columns local relapses, grey columns bone metastases and red columns
soft tissue metastases
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Fig. 2 Patient 12 (a, b) and
patient 18 (c, d). Red arrows point
to a nodular pelvic wall metastasis
(a, b, histologically confirmed)
and to small lymph nodes (c, d)
which present with clearly
pathological tracer uptake in 68Ga-
PSMA PET/CT (b and d) only.
Yellow arrows point to both
catheterized ureters (c, d). Patient
12 presented with a minimal PSA
value (0.01 ng/ml) despite visible
tumour lesions. The PSMA ligand
is therefore able to detect low
differentiated PC. a + c Fusion of
18F-fluoromethylcholine PET and
CT, b + d fusion of 68Ga-PSMA
PET and CT. Colour scales as
automatically produced by the
PET/CT machine
Fig. 3 Patient 13 (a, b) and
patient 18 (c, d). Red arrow in
b points to a liver metastasis
(histologically confirmed, lesion
16 in Fig. 1) visible only in 68Ga-
PSMA PET/CT due to relatively
low background activity
when compared to 18F-
fluoromethylcholine PET. In d, red
arrow points to a lymph node
which presents with clearly
pathological tracer uptake in 68Ga-
PSMA PET/CT despite a beam
hardening artefact (lesion 28 in
Fig. 1). In 18F-fluoromethylcholine
PET/CT, however, there is no
pathological uptake (c). a + c
Fusion of 18F-fluoromethylcholine
PETand CT, b + d fusion of 68Ga-
PSMA PET and CT. Colour scales
as automatically produced by the
PET/CT machine
Eur J Nucl Med Mol Imaging (2014) 41:11–20 17
by a significant decrease of PSAwere indicative of the fact that
PSMA-positive lesions in PET/CTwere metastases of PC.
Discussion
To date, the detection of lesions in the context of biochemical
recurrence of PC is amajor challenge for all imagingmodalities
including choline-based PET/CT [2–13]. The aim of this study
was to compare the established 18F-fluoromethylcholine PET/
CT with a novel 68Ga-labelled PSMA ligand. We retrospec-
tively analysed 37 patients who underwent both 18F-
fluoromethylcholine PET/CT and 68Ga-PSMA PET/CT analy-
sis within a time window of 30 days. In all cases there was
suspected progressive disease following prior conventional
treatment of PC. Most patients were initially referred for 18F-
fluoromethylcholine PET/CT. However, due to reasons men-
tioned before, further 68Ga-PSMA PET/CT was conducted.
Theoretically the order of investigations could introduce a bias
due to possible tumour progression between the first and the
second PET/CT. In reality however it is well known that PC
usually presents with slow growth and noticeable changes
within 30 days are very unlikely. Furthermore, the average time
between both examinations was 11.9 days only.
In the following, numerous essential results of this study
are highlighted and discussed in detail to further demonstrate
the superiority of 68Ga-PSMA PET/CT when compared to
choline. In 86.5 % of the patients at least one lesion charac-
teristic for PC was detected in 68Ga-PSMA PET/CT. This rate
is similar to our previous data [26]. By contrast, only 70.3 %
of the patients presented with pathological findings in 18F-
fluoromethylcholine PET/CT which is similar to the data
reported in the literature [3–13]. 18F-Fluoromethylcholine
PET/CT did not reveal any suspicious lesions in 11 patients,
while only 5 patients presented without any pathological
findings in 68Ga-PSMA PET/CT.
Especially at lower PSA levels, 68Ga-PSMA PET/CT detect-
ed more PC lesions when compared to choline. This was statis-
tically significant as demonstrated in the results. These data are
also similar to our previous report concerning this PSMA ligand
[26]. Also the rates of choline are in agreement with the data
reported in the literature [3–13]. Therefore, 68Ga-PSMA PET/
CT proved to be clearly superior in detecting PC lesions at low
PSA levels when compared to choline-based PET/CT.
Fig. 4 Patient 15. Red arrow points to a vertebral metastasis visible in
68Ga-PSMA PET/CT (a) only. Due to physiological high background
activity in the vertebral column, vertebral metastases are usually difficult
to detect in choline PET (c). Typical for choline PET is also a frequently
high background activity as visible in the maximum intensity projection
(MIP, d). Image data are given as automatically produced by the PET/CT
machine to demonstrate that the filtering of the MIPs was equally set.
Although it appears that the automatically set scales may not be optimal to
detect lesions on theMIP in every case (e.g. lesion in b is better visualized
on the workstation than in this figure), we preferred to avoid changes of
all figures presented in this study. a Fusion of 68Ga-PSMA PET and CT,
b MIP of 68Ga-PSMA PET, c fusion of 18F-fluoromethylcholine PETand
CT, d MIP of 18F-fluoromethylcholine PET. Colour scales as automati-
cally produced by the PET/CT machine
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A significant advantage of 68Ga-PSMA PET/CT is that
lesions characteristic for lymph node metastases frequently
presented with very high contrast when compared to choline
(Fig. 1 and Table 2). 18F-Fluoromethylcholine PET demon-
strated low sensitivity in detecting lymph nodemetastases. This
disadvantage of choline has also been reported in the literature
[6, 7]. The superior contrast in 68Ga-PSMA PET/CT has also
been demonstrated in most skeletal metastases and local re-
lapses (Fig. 1, Tables 2 and 3 in supplementary data). This is
even more significant than the differences of uptake values in
both methods and illustrates one main drawback of choline-
based PET: even at acceptable uptake values, a high back-
ground signal frequently hampers the detection of lesions.
Our study, therefore, demonstrates that metastases and recur-
rent PC usually present with high contrast in 68Ga-PSMA PET/
CT contributing to a significantly improved detection of PC
lesions even at low PSA levels when compared to 18F-
fluoromethylcholine PET/CT. We hypothesize that detection
rates in 68Ga-PSMAPET/CTwill increasewith rising PSA levels
and tumour size. Recently, Chondrogiannis et al. reported about a
proportional correlation between trigger PSA and detection rate
when using choline PET/CT [27]. On the other hand, there was
no relation between PSA and SUV values in both choline- and
PSMA-based PET/CT in our study. With regard to choline, our
results are in agreement with the literature [28, 29]. For the
PSMA tracer, however, no comparable data are available.
Only four PC lesions in two patients presented with a better
contrast in 18F-fluoromethylcholine PET/CT. Possible explana-
tions for this finding are low injected activity of the PSMA
ligand, previous therapies and different biological properties
such as PSMA expression, choline transport and phosphoryla-
tion caused by tumour heterogeneity [21]. Both patients were
injected with relatively low doses of 68Ga-PSMA. However, our
experiences with this tracer suggest that similar or even lower
doses may be suitable to identify lesions with high target to
background contrast [26]. As there were no further differences
regarding other parameters, it is more probable that PSMA
expression in these lesions is low, whereas choline transport
and choline kinase activity are high.
Although further analyses are needed to confirm these find-
ings and to define sensitivity and specificity, our data suggest an
ability of the presented PSMA ligand to detect low differentiated
PC lesions as well (low PSA levels despite multiple metastases
and high initial GSC, e.g. patients 12 and 15). On the other hand,
evidence exists for a low choline uptake in patients with poorly
differentiated PC. In such cases 18F-fluorodeoxyglucose (FDG)
PET/CT can be used to improve the detection of lesions [30]. In
contrast, PSMA expression is usually higher in lesions with
higher GSC than in lesions with lower GSC [31]. The presented
PSMA ligand, therefore, might be useful to reduce multiple
investigations.
Although PSMA-negative PC seems to be rare [21, 32], we
cannot exclude the possibility of false-negative PET/CT
imaging in patients without pathological findings. One other
aspect is the fact that in patients investigated by histology
there were no false-negative or false-positive findings indicat-
ing a high sensitivity and specificity of the PSMA ligand. This
is similar to our experiences with different patients outside this
study examined only with the PSMA ligand who were inves-
tigated by biopsy (data not yet published). Another aspect is
that in cases of multiple metastases or metastases with difficult
access, biopsy is neither indicated nor ethical. However, mul-
tiple other patients who were treated by selective radiation and
131I-PSMA ligands followed by PSA decrease demonstrated
sufficiently that the PSMA-positive lesions were indeed PC.
With the exception of sensitivity and specificity, the most
significant aspects of our study fulfilled the STARD criteria.
However, our study simply followed the experiences of daily
routine and therefore might be of relevance until results that
conform 100 % with STARD are available in the future.
One additional aspect of the presented 68Ga-labelled
PSMA ligand is the fact that no (cost-intensive) cyclotron is
needed. 68Ga can be extracted from a commercially available
68Ge/68Ga radionuclide generator. In contrast, radiolabelling
choline tracers requires isotopes produced by a cyclotron
(e.g. 18F or 11C).
Further analyses are also required to evaluate the charac-
teristics of different types ofmetastases visible by PSMAPET.
Also the question has to be addressed whether dynamic im-
aging might improve detection of lesions close to the urinary
bladder. In addition, we hope that future studies will compare
the HBED-CC conjugated PSMA ligand and other promising
methods of imaging PC, such as PET imaging with
18F-FACBC [14].
Conclusion
This study presents a retrospective comparison between the
established 18F-fluoromethylcholine-based PET/CT and a
novel method of PET imaging with a 68Ga-labelled PSMA
ligand in the diagnosis of recurrent PC. Our experience with
68Ga-PSMA PET/CT strongly suggests that this is an easy to
handle method which can detect PC relapses and metastases
with significantly improved contrast when compared to
choline-based PET/CT. Nevertheless, the most significant
advantages of 68Ga-PSMA PET/CTare the sensitive detection
of lesions even at low PSA levels, of even small lymph node
metastases (primarily due to a high radiotracer uptake) and of
central bone and liver metastases due to low background
signal.
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